

Code Review Panel Communiqué

The Code Review Panel (CRP) held its third formal meeting on 30 October 2013. The following members attended the meeting:

Ms Shane McSpedden (Acting Chairman)	Pfizer Australia
Ms Daniella Dickson	PricewaterhouseCoopers
Ms Sonja Eibl	Bayer
Mr Aaron Guttmann	Bristol-Myers Squibb
Mr Adrian Anderson	Boehringer Ingelheim
Dr Robyn Langham	Australian Medical Association
Dr Beata Niechoda	Shire Australia
Dr Shaun O'Mara	Novo Nordisk
Mr Andrew Roberts	Boehringer Ingelheim
Ms Clare Willmott (standing in for Ms Holly Kania)	Roche Products

Secretariat

Mrs Sophie Hibburd	Medicines Australia
Ms Deborah Monk	Medicines Australia

Apologies

Dr Ken Harvey	CHF
Mr Geoff MacDonald	GlaxoSmithKline (Deputy Chairman)

The CRP:

- Received a verbal report on the two consumer workshop for the Code Review, held in Sydney and Melbourne on 16 and 18 October. The Workshop facilitator's Report will be considered at the next Panel meeting.
- Considered independent legal advice concerning how to ensure that any transparency measure is compliant with the new Privacy legislation.
- Agreed that explicit consent to collect and publish data about payments or transfers of value must be sought from healthcare professionals in advance.
- Discussed a process for developing a standard form of consent for use by companies, which will encourage consistency across the industry in its communications with health professionals on transparency.
- Noted that where consent cannot be obtained or is later withdrawn, in principle these transactions must be reported, in an aggregated manner.
- Considered how to progress obtaining a unique identifier for healthcare professionals, by obtaining further advice from the Australian Health Practitioner Regulation Agency (AHPRA), third party CRM system suppliers and the Office of the Australian Information Commissioner.
- Agreed that activity-based reporting would be the most appropriate reporting model and discussed the activities that should be reported, similar to the European Federation of Pharmaceutical Manufacturers and Associations (EFPIA) model.

The next meeting of the CRP will be held in late November 2013.